April 18 (Reuters) - Bristol-Myers Squibb Co:
* U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR OPDIVO (NIVOLUMAB) IN PREVIOUSLY TREATED PATIENTS WITH SMALL CELL LUNG CANCER AND GRANTS PRIORITY REVIEW
* BRISTOL-MYERS SQUIBB - OPDIVO SUBMISSION BASED ON SAFETY AND EFFICACY DATA FROM SCLC COHORT OF PHASE 1/2 CHECKMATE -032 TRIAL Source text for Eikon: Further company coverage:
